Truncated variant of the mammalian target for rapamycin (MTOR) protein
US8669347B2 · kind B2 · utility
0Cited by
1References
1Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 1, 2008 |
| Grant date | Mar 11, 2014 |
| Priority date | — |
| Expiry date | Dec 4, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2440/14
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.